Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Clinical Study of JTE-052 Ointment - Randomized Controlled and Long-Term Extension Study of JTE-052 Ointment in Japanese Pediatric Patients with Atopic Dermatitis -

Trial Profile

Phase III Clinical Study of JTE-052 Ointment - Randomized Controlled and Long-Term Extension Study of JTE-052 Ointment in Japanese Pediatric Patients with Atopic Dermatitis -

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delgocitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Japan Tobacco
  • Most Recent Events

    • 25 Apr 2019 According to a Torii Pharmaceutical Media Release, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. will aim to submit a marketing application for delgocitinib ointment in Japan, based on the results of this and other clinical studies.
    • 25 Apr 2019 According to a Torii Pharmaceutical Media Release, Primary endpoint of Efficacy the percentage change of the mEASI score from baseline, has met superiority to the vehicle. The favorable tolerability profile on safety was obtained within the treatment period.
    • 24 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top